NSE - Delayed Quote INR

Laurus Labs Limited (LAURUSLABS.NS)

Compare
583.70
-29.35
(-4.79%)
At close: January 10 at 3:30:01 PM GMT+5:30

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Dr. Satyanarayana Chava M.Sc., Ph.D. CEO & Whole Time Director 134.71M -- 1961
Mr. Vantaram Venkata Ravi Kumar Dip in Mgmt., DIS, F.C.M.A. CFO & Whole-Time Director 43.81M -- 1965
Mr. B. V. R. K. Suryadevara Srinivasa Rao Executive Vice President of Manufacturing & Operations -- -- 1968
Mr. Narasimha Rao Chava Executive Vice President of Human Resources -- -- 1968
Dr. Lakshmana Rao Venkata Chunduru M.Sc., Ph.D. Head of Quality & Executive Director 28.73M -- 1962
Mr. Srinivasa Rao Suryadevara B.Sc, M.Sc. Executive Vice President of Manufacturing -- -- 1963
Mr. Chagarlamudi Sita Ramaiah Executive Vice President of Finance -- -- 1973
Mr. Dammalapati Venkata Lakshmi Narasimha Rao Executive Vice President of Synthesis -- -- 1969
Mr. Krishna Chaitanya Chava Executive VP, Head of Synthesis & Ingredients and Executive Director -- -- 1990
Mr. Rajaram Iyer M.B.A. Executive Vice President of Portfolio Management -- -- 1974

Laurus Labs Limited

Serene Chambers
2nd Floor Road No. 7 Banjara Hills
Hyderabad, 500034
India
91 40 3980 4333 https://www.lauruslabs.com
Sector: 
Healthcare
Full Time Employees: 
6,007

Description

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Corporate Governance

Laurus Labs Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

January 24, 2025 at 10:59 AM UTC

Laurus Labs Limited Earnings Date

Recent Events

November 6, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

WINDLAS.NS Windlas Biotech Limited
988.75
-2.69%
 
DIVISLAB.NS Divi's Laboratories Limited
5,771.35
-0.91%
 
GRANULES.NS Granules India Limited
593.60
-2.05%
 
SOLARA.NS Solara Active Pharma Sciences Limited
654.70
-4.07%
 
AJANTPHARM.NS Ajanta Pharma Limited
2,834.20
-3.44%
 
ALKEM.NS Alkem Laboratories Limited
5,376.05
-1.43%
 
NEULANDLAB.NS Neuland Laboratories Limited
14,044.55
-4.02%
 
GLENMARK.NS Glenmark Pharmaceuticals Limited
1,541.70
-3.24%
 
BLISSGVS.NS Bliss GVS Pharma Limited
160.47
-3.88%
 
PPLPHARMA.NS Piramal Pharma Limited
221.25
-6.70%